What kind of company is Dengyue Pharmaceutical? What are the reasons for choosing Dengyue?

Connecting international pharmaceuticals, safeguarding hope for life. As a legitimate importer and wholesaler of new and special drugs authorized by the Hong Kong Department of Health, Hong Kong Dengyue Pharmaceutical Co., Ltd. has always adhered to its original mission in the pharmaceutical industry since its establishment in 2019.

With compliant operation as its bottom line, quality and safety as its core, and patient needs as its guide, it focuses on global supply chain services for new drugs, specialty drugs, and orphan drugs in the fields of major chronic diseases, oncology, and rare diseases. It has now become a professional pharmaceutical distribution enterprise integrating procurement, agency, customs declaration, cold chain logistics, and compliant sales.

A multinational pharmaceutical distributor specializing in the import and export of new drugs, specialty drugs, and rare disease medications, committed to providing cutting-edge and compliant pharmaceutical supply services to global healthcare institutions and patients. Why choose Dengyue?

1.  Qualifications and Compliance:

Dengyue Pharmaceutical holds a pharmaceutical importer/wholesaler license approved by the Hong Kong Department of Health (License No.: 48/2A/2024), subject to strict regulation by Hong Kong government laws, possessing full-chain qualifications for drug procurement, agency, customs declaration, and sales. The company operates in accordance with industry standards such as NMPA/GMP/FDA, ensuring drug quality and supply chain security.

2.  Core Business and Pharmaceutical Agency:

We can supply over 30,000 different drugs. We focus on the import and export of innovative drugs in the fields of major chronic diseases, rare diseases, and oncology, serving institutions including hospitals, pharmacies, and medical distributors. Its distributed pharmaceutical products mainly come from developed countries and regions such as Europe, the United States, Switzerland, and Japan, covering the following key categories:

● Anti-tumor drugs: such as surufatinib, neratinib, memetinib, and erdatinib (BALVERSA®).

● Orphan drugs for rare diseases: such as Forzinity (imamitide hydrochloride, the world's first mitochondrial targeted therapy for Barth syndrome), fenzotinib, and fenfluramine.

● Liver disease treatment drugs: such as bulevirtide (a first-in-class treatment for hepatitis B).

● Antibiotics and immunomodulators: such as ceftazidime-avibactam (Zavicefta) and adalimumab biosimilars (AMJEVITA).

3. Industry Influence and Cutting-Edge Strategy

Dengyue Pharmaceutical not only provides pharmaceutical distribution services but also actively participates in the clinical translation of innovative drugs globally. For example, in the 2026 study of surufatinib combined with immunotherapy for advanced neuroendocrine tumors, its supply chain system supported the rapid implementation of this therapy, promoting the clinical application of the new era of "targeted therapy + immunotherapy." Simultaneously, the company has introduced breakthrough drugs such as Forzinity, filling the gap of "no cure" for rare diseases and helping to move from "symptomatic support" to "etiological treatment."

Relying on a professional pharmaceutical quality inspection team and a physician-led service team, Dengyue Pharmaceutical has established strict standards for inbound quality inspection, warehousing management, and cold chain transportation. It can provide efficient distribution services covering both conventional and temperature-controlled pharmaceuticals. Its service network covers hospitals, chain pharmacies, research institutions, and authorized medical distributors, providing safe, efficient, and reliable pharmaceutical solutions to domestic and international clients.

In the future, Hong Kong Dengyue Pharmaceutical will continue to deepen its involvement in the pharmaceutical and healthcare field, continuously optimize global resource allocation, enhance professional service capabilities, actively promote the efficient circulation of international pharmaceutical resources, and strive to become a trustworthy professional pharmaceutical distribution service provider, contributing continuously to public health and the well-being of the people. We remain true to our original aspirations, uphold our responsibilities, and deliver warmth and care for life.